Benzinga · Sep 30, 2026
HC Wainwright & Co. Maintains Buy on Dyne Therapeutics, Lowers Price Target to $32
HC Wainwright & Co. analyst Ananda Ghosh maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and lowers the price target from $50 to $32.
DY
NASDAQ · DYN
Dyne Therapeutics, Inc.
Healthcare · Biotechnology
$15.40
Down-$0.04 (-0.26%)
Updated Oct 7, 2026, 3:44 AM
SID Score
4.2/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 2.77B
- P/E ratio
- -5.35
- Dividend yield
- 0.00%
- 52-week range
- $14.96 – $27.31
- Volume
- 4.1M
- Avg. volume
- 2.94M
Price performance · DYN
DYN price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
DYN closed at $15.40 after 21 trading sessions, down 24.18% for the selected period.
- Last close
- $15.40
- Period change
- -24.18%
- Period low
- $15.20
- Period high
- $20.31
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $15.50 | $15.59 | $14.925 | $15.40 | 4.1M |
| Oct 5, 2026 | $15.31 | $15.54 | $15.08 | $15.44 | 4.38M |
| Oct 2, 2026 | $16.03 | $16.03 | $15.085 | $15.20 | 2.53M |
| Oct 1, 2026 | $16.01 | $16.28 | $15.52 | $15.82 | 3.7M |
| Sep 30, 2026 | $16.05 | $16.796 | $15.92 | $16.11 | 4.46M |
| Sep 29, 2026 | $16.40 | $16.55 | $15.97 | $16.21 | 2.29M |
| Sep 28, 2026 | $15.86 | $16.43 | $15.63 | $16.34 | 2.31M |
| Sep 25, 2026 | $16.62 | $16.755 | $16.02 | $16.03 | 1.61M |
| Sep 24, 2026 | $16.09 | $16.645 | $15.88 | $16.51 | 3.2M |
| Sep 23, 2026 | $17.08 | $17.081 | $16.18 | $16.23 | 2.64M |
| Sep 22, 2026 | $17.39 | $17.59 | $17.06 | $17.14 | 2.63M |
| Sep 21, 2026 | $17.31 | $17.59 | $16.75 | $17.12 | 3.22M |
| Sep 18, 2026 | $18.07 | $18.15 | $16.96 | $17.11 | 4.85M |
| Sep 17, 2026 | $17.90 | $18.105 | $17.62 | $18.06 | 2.85M |
| Sep 16, 2026 | $18.37 | $18.37 | $17.09 | $17.305 | 2.16M |
| Sep 15, 2026 | $18.52 | $18.62 | $17.87 | $17.90 | 3.03M |
| Sep 14, 2026 | $18.40 | $19.145 | $18.265 | $18.52 | 3.2M |
| Sep 11, 2026 | $18.59 | $18.74 | $17.94 | $18.21 | 3.77M |
| Sep 10, 2026 | $19.025 | $19.025 | $17.93 | $18.42 | 4.71M |
| Sep 9, 2026 | $19.38 | $20.16 | $18.97 | $19.19 | 5.14M |
| Sep 8, 2026 | $17.08 | $20.91 | $17.002 | $20.31 | 17.17M |
Latest DYN news
The latest Smart Investors Daily articles mentioning DYN.
Stock researchCompany · Overview
Company
Market Activity
Research & News
DYN research
Overview
Company profile and research snapshot.
Company profile
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $38.11
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 30, 2026 | Chardan Capital | Buy | — |
| Sep 30, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 29, 2026 | Piper Sandler | Overweight | — |
| Sep 9, 2026 | Baird | Outperform | — |
| Sep 9, 2026 | RBC Capital | Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 29, 2026
Dyne Therapeutics stock rises on positive DM1 trial results
Investing.com -- Dyne Therapeutics Inc (NASDAQ:DYN) shares gained 2.1% in after-hours trading Tuesday following the release of one-year trial data for its experimental DM1 treatment z-basivarsen.
Yahoo · Sep 29, 2026
Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
- Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus a matched natural history cohort across multiple measures at 12 months - - Data continued to support improvement at 6 months in video hand opening time (vHOT) as an early indicator of clinical benefit with z-basivarsen in DM1 - - Dyne continues to expect topline data in Q1 2027 from the ACHIEVE registra
Benzinga · Sep 29, 2026
Dyne Therapeutics Announces Additional One-Year Clinical Data From Phase 1/2 ACHIEVE Trial
- Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus a matched natural
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
